glp-1 or semaglutide vs. Other Receptor Agonists GLP-1 Medications for Weight Loss:

This corresponded to a risk ratio of 0.90 for emergency department visits and 0.86 for hospitalizations

GLP-1(936) retained its glucagonostatic effects after genetic/pharmacological inactivation of the GLP-1 receptor

Daniel Bessesen, chief endocrinologist at the University of Colorado School of Medicine, May 6, 2026 Biomolecules, Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss, March 13, 2025 BMJ, Weight regain after cessation of medication for weight management: systematic review and meta-analysis, Jan

The role of the microbiome in human health and disease: an introduction for clinicians

Mechanisms and pathways of anti-inflammatory activity of DPP-4 inhibitors in cardiovascular and renal protection

Umpierrez, Rodolfo J